Phase III results of imatinib versus interferon plus cytarabine for newly diagnosed chronic phase chronic myelogenous leukemia (CML) patients.26
| . | Imatinib 400 mg . | Interferon + Ara-C . |
|---|---|---|
| All of these differences are highly statistically significant with P < 0.001. Intolerance leading to discontinuation of first-line therapy; Progressive disease to accelerated phase or blast crisis. | ||
| Abbreviations: CHR, complete hematologic response; MCR, major cytogenetic response (Ph+ metaphases < 35%); CCR, complete cytogenetic response. | ||
| CHR | 96% | 67% |
| MCR | 83% | 20% |
| CCR | 68% | 7% |
| Intolerance | 0.7% | 23% |
| Progressive disease | 1.5% | 7% |
| . | Imatinib 400 mg . | Interferon + Ara-C . |
|---|---|---|
| All of these differences are highly statistically significant with P < 0.001. Intolerance leading to discontinuation of first-line therapy; Progressive disease to accelerated phase or blast crisis. | ||
| Abbreviations: CHR, complete hematologic response; MCR, major cytogenetic response (Ph+ metaphases < 35%); CCR, complete cytogenetic response. | ||
| CHR | 96% | 67% |
| MCR | 83% | 20% |
| CCR | 68% | 7% |
| Intolerance | 0.7% | 23% |
| Progressive disease | 1.5% | 7% |